COMMUNICATIONS

The communications corresponding to the 21st Congress of the European Neuroendocrine Association (ENEA 2024), will be published in digital format on this website.

SUBMISSION OF COMMUNICATIONS MODIFY YOUR SUBMISSION

regulations for communications

How to submit ABSTRACTS?

  • Abstracts must be sent exclusively through the online submission form. Click on the buttoms above to make the first submission or to modify an existing one. Please, note that username must be introduce in lowercase, combining letters and numbes and without blank spaces. After the registration to the private area, you will receive an email to establish your password. If you don’t find the email, please, take a look at spam folders and mark the email address as a confidence direction. 
  • The deadline for submission is 23:59 on 16 June 2024.
  • The abstract of the paper must be submitted in English only and in the following order:
    1. Authors: all authors of the paper (surname and first initial) must be entered. The maximum number of authors for each paper will be 12.
    2. Affiliation: place of work, city and country.
    3. Title: the title must be in capital letters and it is advisable not to exceed 25 words.
    4. Abstract: Introduction, material and methods, results and conclusions.

The maximum length will be 450 words (authors, work centres and references do not count).

  • Widely recognised abbreviations will be allowed and others if they have been previously specified in the text.
  • If there is a conflict of interest in the paper, this will be stated in the space provided for this purpose on the submission website and on the first slide corresponding to the oral presentation or at the top of the poster if this is the presentation format.
  • Authors should indicate their preferences regarding the thematic area in which they wish the paper to be included (see “thematic areas” at the end) and the presentation format (oral or poster) for the Scientific Committee to take this into account.
  • An author may only appear as first author on a single communication.
  • The title and abstract must not contain any information that could indicate the origin of the paper. The Technical Secretariat guarantees the anonymity of the authors and the origin of the paper during the evaluation process.
  • Acceptance or rejection of abstracts and the modality will be communicated by e-mail. It will be essential to clearly indicate the e-mail address and contact telephone number (mobile phone) of the first author of the paper.
  • If the abstract of the paper is accepted by the Scientific Committee, at least one of the authors (preferably the first author) must register for the congress in order to be able to present it. If no author is registered before 9 August, the paper will be considered as withdrawn by the author.

reception of communications: steps to follow

  • You can make your abstract in a word processor, and then copy and paste it into the communications reception module.
  • You can access the module as many times as you wish to make changes. The version of the abstract that appears in the abstract module on 16 June will be the one to be evaluated.
  • Only abstracts entered in the abstract module will be evaluated. No other form of abstract submission will be accepted. Accepted abstracts will be reproduced directly from the original, without modification or correction.

EVALUATION AND SELECTION OF ABSTRACTS

  • All abstracts will be evaluated by the Scientific Committee.
  • The decisions of the Scientific Committee will be sent by e-mail to the first author indicating, if accepted, in which format it has been selected (oral, poster or publication).

THEMATIC AREAS

Select an option from the list:

    1. Neuroendocrine physiology and metabolism.
    2. Adrenal Neuroendocrine tumors (Cushings).
    3. Pituitary tumors clinical research.
    4. Pituitary tumors basic/translational research.
    5. Growth Hormone Axis.
    6. NET clinical research.
    7. NET basic/translational research.
    8. Others neuroendocrine-related tumors.
    9. New drug development.
    10. Pediatric neuroendocrinology.
    11. Psychiatric neuroendocrinology.